AgenTus Therapeutics

AgenTus Therapeutics is a privately held biotechnology company based in Lexington, Massachusetts. The company employs 20 people and has generated over $10,000 in revenue. AgenTus Therapeutics focuses on the discovery, development, and commercialization of innovative cell therapies designed to treat a range of diseases, particularly cancer. Their core technology, the iNKT platform, allows for the creation of three main types of therapies: unmodified allogeneic iNKT therapies (ALLO-iNKT), redirected iNKT therapies (RED-iNKT), and CAR-modified therapies (CAR-iNKT). These therapies aim to enhance the body's immune system by supercharging immune effector cells to target and destroy diseased cells. AgenTus Therapeutics' approach centers on developing "off-the-shelf" living drugs, meaning these therapies would be readily available to patients, eliminating the need for individualized manufacturing processes. Interested parties can visit AgenTus Therapeutics' website at agentustherapeutics.com for more information.